Press & News
EMERAMs portfolio company Meona acquires Dr. Heni SOFTWARE, expanding its product portfolio
Munich, 15 March 2019 – Meona Group (“Meona“), a portfolio company of private equity firm EMERAM Capital Partners (“EMERAM“) and an innovation leader in the field of clinical software, acquires Dr. Heni SOFTWARE GmbH & Co. KG (“Dr. Heni SOFTWARE“), a leading provider of high-performance software products which support pharmacists in the preparation, prescription and billing of cytostatic solutions.
With its software, Meona offers a forward-thinking solution for efficient patient care and patient management in hospitals and other facilities. Through the combination with the Belgian company E.care bvba, which develops software to support hospital treatment processes, Meona had already expanded its product range to include the product E.care ED, a process management control solution with intuitive treatment documentation for emergency rooms, in 2017. With the acquisition of Dr. Heni SOFTWARE, which was founded in 1998 by the clinical pharmacist Dr. Josef Heni, Meona once again significantly strengthens its product range and opens up new customer potential.
The two IT solutions Dr. Heni SOFTWARE offers, ZENZY (a program for organizing the production of cytostatic drugs) and the drug tax A-Taxe, are particularly used by hospital and public pharmacies.
Dr. Josef Heni, founder and owner of Dr. Heni SOFTWARE, said: "I am very happy to have found an ideal partner in Meona. I have known Meona's management team for a very long time and I know that with this team our products, ZENZY and A-Taxe, can be successfully further developed.”
PD Dr. med. Tobias Schäfer, Joint Managing Director and CEO of Meona, commented: "Over many years, Dr. Heni has created efficient solutions for hospital pharmacies that are geared toward the needs of the market. We are very pleased to be able to complete the medication workflow with the integration of his solution and to offer the organization of the complex production of cytostatic drugs from a single source.”
Dr. med. Matthias Wuttke, Joint Managing Director and CTO of Meona, added: "We see enormous potential to migrate our existing solutions to a modern IT platform and thus enable customers to make a smooth transition to state-of-the-art, high-performance technologies.”
Fabian Furtmeier, Associate Partner at EMERAM, stressed: "With the acquisition of Dr. Heni SOFTWARE, we continue our Buy & Build strategy for Meona and boost Meona's position as one of the digital innovation leaders in the field of clinical software.”
Since the end of 2017, Meona has been a portfolio company of EMERAM, an independent private equity firm for medium-sized companies in German-speaking countries. EMERAM is a long-term business development partner and supports the company with the consistent implementation of its growth strategy.
The parties have agreed not to disclose any financial details of the transaction. Dr. Josef Heni was advised by Dr. Heni und Partner Steuerberater Rechtsanwälte PartGmbB, Meona by FGvW (Freiburg) under the leadership of Dr. Hendrik Thies. Tax advice was provided by Boris Melzer from Melzer und Kollegen.
A leading innovator in the clinical software sector, the Meona Group was established in 2017 following the merger of healthcare IT companies Meona GmbH and E.care BVBA. Dr. Heni Software GmbH & Co. KG was added to the Group in 2019. Numerous university hospitals and tier-1 hospitals use the company’s software to digitalise and optimise hospital processes, resulting in a substantial improvements in treatment quality and patient care.
Dr. Heni SOFTWARE GmbH & Co. KG was founded in 1998 by the clinical pharmacist Dr. Josef Heni and supports pharmacies in the production and billing of cytostatics and other medicines with its software products ZENZY and A-Taxe. Cytostatic drugs are natural or synthetic substances that inhibit cell growth or cell division. Further information is available at www.heni-software.de
EMERAM Capital Partners is a leading equity investment company for SMEs in German-speaking countries. As a business development partner, we foster the long-term growth of our portfolio companies with capital and expertise.
The funds advised by EMERAM invest in the consumer, technology/software and service sectors. Their total volume currently stands at EUR 400 million. In general, the funds acquire a significant stake in the company and give the respective management team an opportunity to invest, too.